A carregar...
Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia
The phase 3 VIALE-A trial reported that venetoclax in combination with azacitidine significantly improved response rates and overall survival compared with azacitidine alone in older, unfit patients with previously untreated acute myeloid leukemia (AML). However, the cost-effectiveness of azacitidin...
Na minha lista:
| Publicado no: | Blood Adv |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7903235/ https://ncbi.nlm.nih.gov/pubmed/33591323 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003902 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|